Remix Therapeutics

WATERTOWN, MA · Founded 2019 · Biotech · Still private

Claim this profile

Follows are private to you and power your alerts

Updated · remixtx.com

Sector
Biotech
Headquarters
WATERTOWN, MA
Founded
2019
Latest Form D
$13.7M, Jan 2024
Total capital
$13.7M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$13.7M
1 Form D · last Jan 2024
34 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
40 pending

Capital timeline

2024FEDERAL ↑EQUITY ↓Cumulative $13.7M1st Form D$13.7M
2024FEDERAL ↑EQUITY ↓Cumulative $13.7M1st Form D$13.7M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$13.7M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Heather WassermanExecutive OfficerNamed in SEC Form D filings
  • Jeff GoaterDirectorNamed in SEC Form D filings
  • Kevin BittermanDirectorNamed in SEC Form D filings
  • Matthew PattersonDirectorNamed in SEC Form D filings
  • Michael RomeDirectorNamed in SEC Form D filings
  • Peter SmithExecutive Officer, DirectorNamed in SEC Form D filings
Show all 8 people
  • Robert GagnonExecutive OfficerNamed in SEC Form D filings
  • Scott BillerDirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 40
  • PendingMethods And Compositions For Modulating Splicing At Alternative Splice SitesUSPTOApplication 19103514
  • PendingCompounds And Methods For Modulating SplicingUSPTOApplication 18688100
  • PendingCompounds And Methods For Modulating Nucleic Acid SplicingUSPTOApplication 18700632
Show all 40 patent records
  • Methods And Compositions For Modulating Splicing At Alternative Splice SitesMar 5, 2026 · Application 19103514Pending
  • Compounds And Methods For Modulating SplicingOct 30, 2025 · Application 18688100Pending
  • Compounds And Methods For Modulating Nucleic Acid SplicingOct 30, 2025 · Application 18700632Pending
  • Compounds And Methods For Modulating SplicingOct 23, 2025 · Application 18726008Pending
  • Compounds And Methods For Modulating SplicingMay 15, 2025 · Application 18688087Pending
  • 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE Derivatives And Related Compounds As Modulators For Splicing Nucleic Acids And For The Treatment Of Proliferative DiseasesMar 20, 2025 · Application 18726007Pending
  • Compounds And Methods For Modulating SplicingMar 13, 2025 · Application 18713561Pending
  • Compounds And Methods For Modulating SplicingDec 12, 2024 · Application 18688088Pending
  • Compounds And Methods For Modulating SplicingDec 5, 2024 · Application 18688081Pending
  • Compounds And Methods For Modulating SplicingNov 7, 2024 · Application 18688098Pending
  • Compounds And Methods For Modulating Nucleic Acid SplicingNov 7, 2024 · Application 18700515Pending
  • Compounds And Methods For Modulating SplicingAug 29, 2024 · Application 17917868Pending
  • Compounds And Methods For Modulating SplicingAug 22, 2024 · Application 17917842Pending
  • 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE Derivatives And Related Compounds As Modulators For Splicing Nucleic Acids And For The Treatment Of Proliferative DiseasesJul 18, 2024 · Application 18014057Pending
  • Compounds And Methods For Modulating SplicingJul 11, 2024 · Application 17802863Pending
  • Fused Bicyclic Compounds Useful For Modulating Nucleic Acid SplicingJun 13, 2024 · Application 17802833Pending
  • Oligonucleotides Useful For Modulation Of SplicingJan 18, 2024 · Application 18033748Pending
  • 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE Derivatives And Related Compounds As Modulators For Splicing Nucleic Acids And For The TreJan 4, 2024 · Application 18014059Pending
  • Heterocyclic Amides And Their Use For Modulating SplicingNov 16, 2023 · Application 17802719Pending
  • Pyridazine Derivatives For Modulating Nucleic Acid SplicingNov 16, 2023 · Application 17802747Pending
  • Compounds And Methods For Modulating SplicingJun 1, 2023 · Application 17917734Pending
  • Compounds And Methods For Modulating SplicingMay 25, 2023 · Application 17917729Pending
  • Thiophenyl Derivatives Useful For Modulating Nucleic Acid SplicingMay 11, 2023 · Application 17802866Pending
  • Compounds And Methods For Modulating SplicingMay 11, 2023 · Application 17802827Pending
  • Pyridazine Derivatives For Modulating Nucleic Acid SplicingMay 11, 2023 · Application 17802702Pending
  • Compounds And Methods For Modulating SplicingApplication PCTUS2024033680Pending
  • Compounds And Methods For Modulating SplicingApplication PCTUS2024033683Pending
  • Compounds And Methods For Modulating SplicingApplication 19492981Pending
  • Compounds And Methods For Modulating SplicingApplication 19492989Pending
  • Methods And Compositions For Modulating Splicing At Alternative Splice SitesApplication PCTUS2023030113Pending
  • Compounds And Related Methods Useful For Degradation Of Cyclin K And Inhibition Of Cyclin Dependent KinasesApplication PCTUS2025026371Pending
  • Compounds And Methods For Modulating SplicingApplication 19160794Pending
  • Compounds And Methods For Modulating SplicingApplication PCTUS2024018234Pending
  • Compounds And Methods For Modulating SplicingApplication PCTUS2024018251Pending
  • Compounds And Related Methods Useful For Degradation Of Cyclin K And Inhibition Of Cyclin Dependent KinasesApplication 63681769Pending
  • Compounds And Methods For Modulating SplicingApplication PCTUS2024018166Pending
  • Compounds And Methods For Modulating SplicingApplication PCTUS2023010228Pending
  • Compounds And Related Methods Useful For Degradation Of Cyclin K And Inhibition Of Cyclin Dependent KinasesApplication 63691996Pending
  • Compounds And Related Methods Useful For Degradation Of Cyclin K And Inhibition Of Cyclin Dependent KinasesApplication PCTUS2025030817Pending
  • Compounds And Methods For Modulating SplicingApplication PCTUS2023010242Pending
  • Matchpoint TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Obsidian TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • SUNNYLIFE PHARMA INC.Similar federal contract value in Biotech · null in contracts
  • Renasant BioSimilar federal contract value in Biotech · null in contracts
  • Sionna TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • NEOKERA, LLCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .